Abstracts

4-YEAR OUTCOMES OF B/F/TAF IN TREATMENT-NAIVE ADULTS

Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is a guidelines-recommended single-tablet regimen for people with HIV-1 (PWH). We present cumulative outcomes from open-label extension (OLE) that followed 144 Weeks (W) of blinded treatment in phase 3 studies in treatment-naïve PWH. We conducted 2 randomized, double-blind, phase 3 studies of B/F/TAF in treatment-naïve adults – Study 1489: B/F/TAF vs dolutegravir/abacavir/lamivudine…

SWITCHING TO DTG/3TC FDC IS NONINFERIOR TO TBR FOR 96 WEEKS: TANGO SUBGROUP ANALYSES

The 2-drug regimen (2DR) of DTG/3TC reduces the number of antiretroviral agents taken by individuals treated for HIV-1 infection, when compared to traditional 3DRs. DTG/3TC is non-inferior to DTG+TDF/FTC in HIV-1 infected ART-naïve adults (GEMINI) through Week 144 and in ART-experienced, virologically suppressed participants switching from a TAF-based 3/4DR (TANGO) through Week 96. Here we…

W96 EFFICACY OF 4/7 DAYS MAINTENANCE ART STRATEGY: ANRS-170 QUATUOR TRIAL

Intermittent treatment could improve the convenience, tolerability and cost of ART. We have previously demonstrated in the QUATUOR trial the non-inferiority of maintenance 4 days-a-week (4/7days) versus 7/7days in patients (pts) under triple therapy with either PI, NNRTI, or InSTI based regimen: 95.6% vs 97.2% treatment success at W48. ClinicalTrials.gov:NCT03256422. We report here the W96…

STRUCTURAL BASIS FOR VIRAL RESISTANCE TO LONG-ACTING HIV-1 CAPSID INHIBITOR GS-6207

GS-6207 (Lenacapavir, Gilead Sciences) is an experimental long-acting and highly potent HIV-1 capsid (CA) inhibitor. Viral breakthrough assays in cell culture identified a number of HIV-1 CA substitutions including M66I, Q67H, N74D and Q67H/N74D that confer substantial resistance to the inhibitor. Furthermore, the Q67H capsid substitution has emerged in HIV-1 infected patients receiving GS-6207. We…